Expert Q&As
First interactions with EMA - Q&A 8
What are Early Access Programs (EAPs) in Europe, and how can they help gather real-world data?
Access decades of experience
What’s Inside the Q&A:
Early Access Pathways
Discover how Europe’s pre-approval mechanisms open controlled, country-specific routes for patients to receive investigational therapies.
Real-World Data Opportunities
See how early access participation becomes a strategic channel for gathering practical evidence that strengthens your broader development story.
Physician and Patient Engagement
Unpack how early use builds familiarity, advocacy, and clinical experience that can influence adoption once approval arrives.
Program Design and Execution
Understand the operational choices, safety requirements, and regulatory guardrails that define a compliant and effective early access strategy.
Download our Expert Q&A
Discover our latest news
Expert Q&As
First interactions with EMA - Q&A 1
What are the different regulatory pathways available when expanding to Europe and which one is the best fit for me?
Expert Q&As
First interactions with EMA - Q&A 2
How does the EU drug development landscape differ from the US ?
Expert Q&As
First interactions with EMA - Q&A 7
What regulatory pathway missteps should we avoid, and how can we streamline our EU dossier preparation?
